middle.news
INOVIQ Advances Ovarian Cancer Test and CAR-Exosome Therapeutics with Solid Cash Backing
9:08am on Tuesday 28th of April, 2026 AEST
•
Biotechnology
Read Story
INOVIQ Advances Ovarian Cancer Test and CAR-Exosome Therapeutics with Solid Cash Backing
9:08am on Tuesday 28th of April, 2026 AEST
Key Points
EXO-OC™ clinical study cancer-control group due June 2026
US commercialisation progress targeting LDT-ready status by December 2026
CAR-exosome therapeutics program refined and accelerated post-CSO review
Promega places third EXO-NET® order amid growing diagnostic partnerships
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE